Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Kiyonobu Ueno"'
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2618-2621 (2023)
Abstract Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the trea
Externí odkaz:
https://doaj.org/article/0b677e61d0a441c2a1a51cdc45a6a716
Autor:
Satoshi Tanaka, Yoshihiro Takayama, Riiko Kitou, Ryo Asakawa, Satoshi Tobita, Akihiro Ike, Masahiro Kawada, Suguru Yamamoto, Kiyonobu Ueno
Publikováno v:
Clinical Case Reports, Vol 10, Iss 12, Pp n/a-n/a (2022)
Abstract Coronavirus disease 2019 (COVID‐19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID‐19 is relatively uncommon. We herein report a 60‐year‐old man with bil
Externí odkaz:
https://doaj.org/article/5d62adbc0fa841d18fee3c8a13ac8b5d
Autor:
Kohei Matsuo, Satoshi Tanaka, Masayuki Sakata, Hiroki Takeda, Akihiro Nagata, Masashi Mori, Rie Ito, Yoshifumi Yamamoto, Kiyonobu Ueno, Atsuhiko Uno
Publikováno v:
Case Reports in Otolaryngology, Vol 2021 (2021)
Primary nasopharyngeal mycobacteriosis is a rare disease. We present a case in which skull base bone erosion appeared and was alleviated during the course of the treatment. Bone complications occur in osteoarticular mycobacteriosis, but their occurre
Externí odkaz:
https://doaj.org/article/3ac46010270543d5bf7a155431fb88a0
Autor:
Satoshi Tanaka, Ryo Asakawa, Kiyohide Komuta, Satoshi Tanizaki, Tomohiro Kanai, Muneyoshi Kuroyama, Kohki Shimazu, Junji Uchida, Takayuki Yakushijin, Kiyonobu Ueno
Publikováno v:
Respiratory Medicine Case Reports, Vol 31, Iss , Pp 101266- (2020)
Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer (NSCLC) and extensive disease s
Externí odkaz:
https://doaj.org/article/9a95dd3ca2014315839d8f1026447deb
Publikováno v:
Medicine; 7/26/2024, Vol. 103 Issue 30, p1-4, 4p
Autor:
Satoshi Tanaka, Yoshihiro Takayama, Riiko Kitou, Ryo Asakawa, Satoshi Tobita, Akihiro Ike, Masahiro Kawada, Suguru Yamamoto, Kiyonobu Ueno
Publikováno v:
Clinical Case Reports. 10
Autor:
Satoshi Tanizaki, Kinnosuke Matsumoto, Akihiro Tamiya, Yoshihiko Taniguchi, Yoshinobu Matsuda, Junji Uchida, Kiyonobu Ueno, Hayato Kawachi, Motohiro Tamiya, Takafumi Yanase, Hidekazu Suzuki, Kyoichi Okishio
Purpose Ramucirumab (RAM) and docetaxel (DOC) are commonly used after first-line therapy including immune checkpoint inhibitor (ICI) for advanced non-small cell lung cancer (NSCLC). Therefore, it is important to evaluate sequential strategies of RAM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::008e7ade015b5aac2b04111b3011b487
https://doi.org/10.21203/rs.3.rs-2203249/v1
https://doi.org/10.21203/rs.3.rs-2203249/v1
Autor:
Satoshi Tanaka, Kiyohide Komuta, Ryo Asakawa, Satoshi Tanizaki, Tomohiro Kanai, Junji Uchida, Satoshi Fujimi, Kiyonobu Ueno
Publikováno v:
Journal of Bronchology & Interventional Pulmonology. 29:e31-e33
Autor:
Yoshihiko Taniguchi, Hidekazu Suzuki, Takafumi Yanase, Tomonori Hirashima, Akihiro Tamiya, Motohiro Tamiya, Satoshi Tanizaki, Kinnosuke Matsumoto, Kiyonobu Ueno, Hayato Kawachi, Junji Uchida, Yoshinobu Matsuda, Shinji Atagi
Publikováno v:
Transl Lung Cancer Res
Background Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effec